| scholarly article | Q13442814 |
| P50 | author | Andrea Boscolo Bragadin | Q94591582 |
| P2093 | author name string | Fiorella Calabrese | |
| PierFranco Conte | |||
| Matteo Fassan | |||
| Alberto Amadori | |||
| Giorgia Nardo | |||
| Valentina Guarneri | |||
| Laura Bonanno | |||
| Elisabetta Zulato | |||
| Alberto Pavan | |||
| Stefano Indraccolo | |||
| Giulia Pasello | |||
| Paola Del Bianco | |||
| Ilaria Attili | |||
| Lorenza Pasqualini | |||
| Martina Verza | |||
| P2860 | cites work | Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. | Q27851702 |
| KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients | Q28077570 | ||
| Circulating mutant DNA to assess tumor dynamics | Q28289337 | ||
| Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. | Q35591583 | ||
| Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study | Q36359821 | ||
| Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer | Q37536958 | ||
| Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial | Q38407938 | ||
| Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. | Q38771051 | ||
| Integrating liquid biopsies into the management of cancer | Q39157824 | ||
| ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study | Q39549460 | ||
| Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. | Q39709734 | ||
| Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer | Q40364937 | ||
| A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial | Q40381235 | ||
| Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma. | Q40464089 | ||
| Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment. | Q40477701 | ||
| Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. | Q40482977 | ||
| Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients. | Q45993942 | ||
| Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution | Q46365334 | ||
| Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. | Q50059462 | ||
| Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. | Q50128100 | ||
| False positive plasma genotyping due to clonal hematopoiesis | Q52641869 | ||
| Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC | Q57165113 | ||
| Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma | Q57232070 | ||
| Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer | Q57806191 | ||
| Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q59587212 | ||
| New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness | Q90706520 | ||
| Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy | Q91332386 | ||
| NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020 | Q91725552 | ||
| P4510 | describes a project that uses | RStudio | Q4798119 |
| P577 | publication date | 2020-05-07 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer |
Search more.